Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Interaction with the Extracellular Matrix Maintains Tumor Dormancy

By LabMedica International staff writers
Posted on 14 Aug 2008
Cancer researchers have used a three-dimensional cell culture system that mimics the microenvironment within the body to identify the molecular signals that cause long dormant cancer cells to resume active growth.
Metastatic breast cancer may emerge from latent tumor cells that remain quiescent at disseminated sites for many years. More...
For example, approximately 30% of breast cancer patients diagnosed with early-stage disease have been found to have breast cancer cells in their bone marrow. However, these cells seem to exist primarily as micrometastases that do not manifest themselves clinically in any way. Although many of these disseminated tumor cells may not survive for extended periods, a subset of them may represent latent but viable cells that could begin to proliferate years later.

Studies to identify the mechanisms that regulate the switch from dormancy to proliferative metastatic growth have suffered from the lack of experimental models of tumor cell dormancy.

In the current study, investigators at the [U.S.] National Cancer Institute (Bethesda, MD, USA) employed a three-dimensional cell culture system that allowed them to observe the interaction between tumor cells and surrounding extracellular matrix (ECM) under conditions closely resembling those inside the body.

They reported in the August 1, 2008, online edition of the journal Cancer Research that the tumor microenvironment was the critical regulator of cancer progression. The ECM significantly affected tumor biology and progression by providing factors for cell growth and survival and for stimulating the growth of new blood vessels to feed the tumor. Furthermore, cell adhesion to the ECM triggered signaling pathways that controlled various phases of cell growth.

Senior author Dr. Jeffrey E. Green, a senior investigator at the National Cancer Institute's laboratory of cell biology and genetics, said, "Recent evidence suggests that, in many cases, tumor cells have already seeded metastatic sites even when the primary tumor is diagnosed at an early stage. We hope that, with additional studies, we can begin to discover new ways to therapeutically keep the dormant-to-active switch in the "off” position, thus limiting the chance that micrometastases become active in later life.”

Related Links:
National Cancer Institute

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.